Olisaemeka Zikora Akunne

Olisaemeka Zikora Akunne

Auto-generated profile, based on publicly available information

Olisaemeka Zikora Akunne

Department of Pharmacy, ASK Medical and Diagnostic Center, Abuja, FCT, Nigeria

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Clinical and Experimental Vaccine Research
Verified
Journal Article
Open access
PDF file
BEBlessing Nkechi Emmanuel
Blessing Nkechi Emmanuel
AIAbubakar Nuhu Ishaq
Abubakar Nuhu Ishaq
OAOlisaemeka Zikora Akunne
Olisaemeka Zikora Akunne
USUmar Faruk Saidu
Umar Faruk Saidu
Emmanuel BN, et al. Clin Exp Vaccine Res. 2024 Apr;13(2):121-131. https://doi.org/10.7774/cevr.2024.13.2.121

27 December 2024 in International Journal of Molecular and Immuno Oncology
Verified
Journal Article
Open access
OAOlisaemeka Zikora Akunne
Olisaemeka Zikora Akunne
OAOgochukwu Emilia Anulugwo
Ogochukwu Emilia Anulugwo
MAMaduabuchi Gabriel Azu
Maduabuchi Gabriel Azu
Cancer immunotherapy has revolutionized oncology by harnessing the body’s immune system to target and eradicate malignant cells. This review delves into emerging strategies in cancer immunotherapy, focusing on novel approaches and future directions of this rapidly evolving field. Key areas of exploration include immune checkpoint inhibitors (ICIs), chimeric antigen receptor (CAR) T-cell therapy, and cancer vaccines. ICIs, which target proteins such as cytotoxic T-lymphocyte antigen-4 and programmed cell death-1/programmed cell death ligand 1, have shown significant efficacy in various cancers, transforming clinical outcomes. CAR-T cell therapy, with its ability to genetically modify T-cells to attack cancer cells, has demonstrated remarkable success in hematologic malignancies and is being adapted for solid tumors. Cancer vaccines designed to stimulate an immune response against specific tumor antigens are also advancing with promising clinical results. Despite these advances, challenges such as immunogenicity, side effects, and treatment resistance remain. This review provides a comprehensive overview of the latest developments, clinical trials, and future perspectives in cancer immunotherapy, highlighting the potential for these strategies to redefine cancer treatment.

28 October 2025 in American Journal of Pharmacotherapy and Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
OAOlisaemeka Zikora Akunne
Olisaemeka Zikora Akunne
BEBlessing Nkechi Emmanuel
Blessing Nkechi Emmanuel
USUmar Faruk Saidu
Umar Faruk Saidu
AAAyobami Sunday Akinnawo
Ayobami Sunday Akinnawo
NANasiru Ademola Adeyemi
Nasiru Ademola Adeyemi
AFAnne Amina Freitas
Anne Amina Freitas
Antibiotic resistance (AR) has become a critical global health crisis, threatening the efficacy of antibiotics and increasing healthcare costs, morbidity, and mortality. The One Health approach, which emphasizes the interconnectedness of human, animal, and environmental health, is increasingly recognized as an essential framework for addressing the complex drivers of AR. This review explores the mechanisms of resistance, such as genetic mutations, horizontal gene transfer, and biofilm formation, along with contributing factors such as the overuse of antibiotics in healthcare and agriculture. We assess both traditional and emerging strategies to combat AR, including antimicrobial stewardship, the development of new antibiotics, and alternative therapies such as bacteriophages, probiotics, and metal complexes. In addition, innovative approaches such as nanotechnology, combination therapies, and precision medicine are highlighted as promising tools for AR mitigation. Through case studies, this paper illustrates the effectiveness of the One Health approach in managing zoonotic diseases and antimicrobial resistance, while also underscoring the need for transdisciplinary collaboration to secure a sustainable and effective future for antibiotic use.

22 August 2025 in Discover Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
OAOlisaemeka Zikora Akunne
Olisaemeka Zikora Akunne
LOLynda Ify Onyebuchukwu
Lynda Ify Onyebuchukwu
MAMaduabuchi Gabriel Azu
Maduabuchi Gabriel Azu
JOJennifer Chinaza Ogwurumba
Jennifer Chinaza Ogwurumba
Background Pancreatic neuroendocrine tumours (pNETs), especially in metastatic or unresectable stages, pose major therapeutic challenges. Conventional treatments often show limited effectiveness, creating the need for novel strategies. Nanoparticle-based therapies have emerged as a promising approach. These therapies enable precise drug delivery using the enhanced permeability and retention (EPR) effect, which allows for targeted tumour treatment and reduced systemic toxicity. Main body Nanoparticle-based therapies can encapsulate a variety of therapeutic agents, including cytotoxic drugs and molecular inhibitors, offering the potential for personalised treatment strategies. Recent pharmacological advancements, such as the multi-kinase inhibitors sorafenib, lenvatinib, and axitinib, target key tumour growth and angiogenesis pathways, improving treatment outcomes. In addition, peptide receptor radionuclide therapy (PRRT) and targeted therapies, including tyrosine kinase inhibitors (TKIs), provide alternative approaches that enhance efficacy while reducing adverse effects. The integration of nanoparticle-based delivery systems, including gold, silver, and lipid nanoparticles, enhances drug targeting and controlled release. However, the clinical translation of these technologies remains hindered by factors such as tumour heterogeneity, drug resistance, and challenges related to manufacturing, stability, and regulatory approval. Despite these barriers, advances in “smart” nanoparticles and personalised nanomedicine continue to drive progress, optimising therapeutic precision and minimising toxicity. Short conclusion While challenges persist, nanoparticle-based therapies offer considerable potential for improving pNET treatment. Ongoing research and multidisciplinary collaboration are crucial to overcoming existing limitations, facilitating clinical translation, and ultimately enhancing patient outcomes.

9 July 2024 in American Journal of Pharmacotherapy and Pharmaceutical Sciences
Verified
Journal Article
Open access
OAOlisaemeka Zikora Akunne
Olisaemeka Zikora Akunne
OAOgochukwu Emilia Anulugwo
Ogochukwu Emilia Anulugwo
Cardiovascular disease (CVD) poses a significant global health concern, contributing to nearly 30% of global deaths. Its prevalence is on the rise, necessitating a deeper understanding of associated risk factors including hypertension, cardiac hypertrophy, and diabetes. Addressing these risk factors is crucial in preventing or slowing the onset of heart failure (HF), a complex chronic condition with high morbidity and mortality rates. This review aims to explore innovative strategies for preventing or delaying HF, focusing on cardiovascular risk (CV) factors. Specifically, it delves into the link between hypertension, cardiac hypertrophy, diabetes, and HF emphasizing the importance of identifying new therapeutic approaches. A comprehensive examination of existing literature, clinical trials, and experimental models forms the basis of this review providing insights into the interconnected nature of cardiovascular risk factors and the efficacy of combination therapies. Evidence from diverse sources supports the adoption of a multifaceted approach to HF prevention. The review underscores the complex associations between hypertension, cardiac hypertrophy, diabetes, and HF highlighting the need for innovative therapeutic interventions. Clinical trials demonstrate promising outcomes with synergistic therapies such as angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors showcasing improved efficacy over single-agent interventions. In conclusion, adopting a multifaceted approach to HF prevention considering the interplay of various risk factors. Such an approach holds the potential for substantial benefits including simultaneous targeting of multiple pathways, individualized care, enhanced patient motivation, and reduced healthcare costs. Further research should focus on optimizing combination therapies and identifying patient population that stands to gain the most from these interventions providing a pathway towards improved cardiovascular health globally.